Table 3 |
|||
|
Drug survival at one, two, and three years by diagnosis |
|||
|
Drug survival [95% confidence interval] |
|||
|
|
|||
|
Diagnosis |
One year |
Two years |
Three years |
|
|
|||
|
Rheumatoid arthritis |
0.83 [0.81–0.84] |
0.72 [0.71–0.74] |
0.65 [0.63–0.67] |
|
All spondylarthritis |
0.88 [0.86–0.90]* |
0.82 [0.79–0.84]* |
0.74 [0.71–0.78]* |
|
Ankylosing spondylitis |
0.88 [0.85–0.91] |
0.82 [0.78–0.86] |
0.76 [0.70–0.80] |
|
Psoriatic arthritis |
0.88 [0.84–0.90] |
0.81 [0.77–0.84] |
0.73 [0.67–0.78] |
|
Undifferentiated spondylarthritis |
0.88 [0.81–0.91] |
0.83 [0.76–0.88] |
0.72 [0.60–0.80] |
|
Crohn's related spondylarthritis |
0.90 [0.79–0.95] |
0.86 [0.73–0.93] |
0.82 [0.69–0.91] |
|
Other spondylarthritis |
0.79 [0.53–0.92] |
0.61 [0.31–0.81] |
0.61 [0.31–0.81] |
|
|
|||
|
*p of the difference versus survival at the same time in rheumatoid arthritis < 0.001 (by log-rank test). |
|||
|
Carmona et al. Arthritis Research & Therapy 2006 8:R72 doi:10.1186/ar1941 |
|||